Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...
March 07, 2025 09:28 ET | Source: AVACTA GROUP PLC

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...
March 07, 2025 08:58 ET | Source: AVACTA GROUP PLC

Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update

LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting...
January 16, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase 1b expansion cohorts...
January 13, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Appoints Brian Hahn as Chief Financial Officer

LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...